INTS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Intensity Therapeutics resumed patient treatment in the Phase 2 INVINCIBLE-4 trial for triple-negative breast cancerJul 15, 2026
- Intensity Therapeutics provided an update on the Phase 2 presurgical INVINCIBLE-4 study in triple-negative breast cancerMar 12, 2026
- Intensity Therapeutics reports INVINCIBLE-4 presurgical triple-negative breast cancer study updateSep 10, 2025
- Intensity Therapeutics announces INT230-6 achieved 100% complete response in preclinical models of malignant peripheral nerve sheath tumorsJun 30, 2025
- Intensity Therapeutics' Phase 3 INVINCIBLE-3 sarcoma study selected for presentation at ASCO 2025 Annual MeetingMay 29, 2025